GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeraMED Ltd (ASX:HMD) » Definitions » LT-Debt-to-Total-Asset

HeraMED (ASX:HMD) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is HeraMED LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. HeraMED's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

HeraMED's long-term debt to total assets ratio stayed the same from Jun. 2023 (0.00) to Jun. 2024 (0.00).


HeraMED LT-Debt-to-Total-Asset Historical Data

The historical data trend for HeraMED's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeraMED LT-Debt-to-Total-Asset Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.05 0.06 - - -

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

HeraMED LT-Debt-to-Total-Asset Calculation

HeraMED's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/3.009
=0.00

HeraMED's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=0/4.67
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeraMED  (ASX:HMD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


HeraMED LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of HeraMED's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


HeraMED Business Description

Traded in Other Exchanges
Address
201, 697 Burke Road, Suite 4, Camberwell, VIC, AUS, 3124
HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.

HeraMED Headlines

No Headlines